Business

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients

Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy requirements for approval in the U.S. and ChinaNCX 470 was also superior to latanoprost in the reduction of intraocular pressure (IOP) from baseline (p<0.05) at 3 out of 6 timepoints and numerically greater at 5 out of 6 timepointsNCX 470 0.1% was safe and well tolerated New Drug App